KSQ Therapeutics Secures $80 Million Financing and Advances Broad Pipeline of Cancer Therapies Including Its First Adoptive T-Cell Therapy Program for PD 1 Resistant Solid Tumors

from Venture Capital Access Online: Latest Venture Capital and Private Equity News https://ift.tt/2xM3GgJ
via IFTTT